Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
10/1/1997
1.
Phase III Randomized, Double-Blind Study of 5-FU/SMS 201-995 pa LAR vs 5-FU/Placebo for Unresectable Stage II or Stage III/IV Pancreatic Cancer (Summary Last Modified 10/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
SANDOZ-SMSM-304-E-00
NCI-V95-0798
Last Modified:
12/1/1998
2.
Phase III Randomized Double-Blind Study of Tamoxifen/Octreotide Pamoate vs Tamoxifen/Placebo in Women with Locally Recurrent or Metastatic Breast Cancer (Summary Last Modified 12/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
SANDOZ-SMST-302
NCI-V96-0934
Last Modified:
11/9/2006
3.
Phase III Study of the Addition of Octreotide Pamoate (SMS 201-995 pa LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Women With Axillary Node Negative, Estrogen Receptor Positive, Primary Invasive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
Not specified
NCI
NSABP-B-29
NCT00002967, NSABP-B-29
4.
Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
CSMS995ADE05
NCT00171873
Last Modified:
12/1/2000
5.
Phase I Study of Octreotide Pamoate With or Without Tamoxifen in Patients With Osteosarcoma (Summary Last Modified 12/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
25 and under (at time of diagnosis)
NCI
NCI-95-C-0119I
NCI-T96-0047N, T96-0047
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute